“…Prospective controlled studies and double-blind, placebo-controlled randomized clinical trials have reported much lower SLIT dropout rates when compared with observational studies ( 25 , 26 ). Dropout rates reported by other studies range from 23.2 to 65% ( 27 – 30 ). Interestingly, a study with a larger sample size showed a trend of a higher dropout rate compared with a study with a small sample size ( 25 ), which may also partly explain the high dropout rate in the current study.…”
Purpose: Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are effective in reducing symptoms and medication scores and inducing long-term efficacy in patients with allergic rhinitis (AR). However, SLIT has been associated with poor patient adherence. This study investigates the factors impacting dropout rates from SLIT in house dust mite (HDM)-sensitized AR patients.Methods: A retrospective study was performed to analyze dropout rates and reasons in AR patients receiving Dermatophagoides farinae (Der f) SLIT with a follow-up period of 2 years.Results: A total of 719 HDM-sensitized AR patients received Der f-SLIT. Dropout rates increased with time and most occurred after 1 year of SLIT. By month 24, 654 (91%) patients had discontinued SLIT. The dropout rates by month 24 were 100, 90.1, and 91.1% in children <5 years old, children aged 5–18 years old, and adults ≥ 18 years old, respectively. Combination with allergic asthma and mono- or multi-sensitization to other aeroallergens did not affect the dropout rates. The most common self-reported reasons for dropouts were refusal of continuation, dissatisfaction with the efficacy, transition to SCIT, and adverse effects. Refusal of continuation increased with age, whereas transition to SCIT decreased with age. Ninety-seven cases transitioned from SLIT to SCIT, and the transition rates increased with time. Comorbid allergic asthma did not affect the transition rates. However, multi-sensitization was associated with a slightly higher rate of transition to SCIT. The most common reason for the transition was dissatisfaction with the efficacy (54.6%), which was only reported by patients older than 5 years. For children who began SLIT at younger than 5 years old, the most common reason (81.2%) for transition was age reaching 5 years.Conclusions: HDM-SLIT has a very high dropout rate, which is mainly due to refusal of continuation and dissatisfaction with the efficacy. Transitioning from SLIT to SCIT may help keep these patients on AIT and thus increase adherence and long-term efficacy.
“…Prospective controlled studies and double-blind, placebo-controlled randomized clinical trials have reported much lower SLIT dropout rates when compared with observational studies ( 25 , 26 ). Dropout rates reported by other studies range from 23.2 to 65% ( 27 – 30 ). Interestingly, a study with a larger sample size showed a trend of a higher dropout rate compared with a study with a small sample size ( 25 ), which may also partly explain the high dropout rate in the current study.…”
Purpose: Both subcutaneous immunotherapy (SCIT) and sublingual immunotherapy (SLIT) are effective in reducing symptoms and medication scores and inducing long-term efficacy in patients with allergic rhinitis (AR). However, SLIT has been associated with poor patient adherence. This study investigates the factors impacting dropout rates from SLIT in house dust mite (HDM)-sensitized AR patients.Methods: A retrospective study was performed to analyze dropout rates and reasons in AR patients receiving Dermatophagoides farinae (Der f) SLIT with a follow-up period of 2 years.Results: A total of 719 HDM-sensitized AR patients received Der f-SLIT. Dropout rates increased with time and most occurred after 1 year of SLIT. By month 24, 654 (91%) patients had discontinued SLIT. The dropout rates by month 24 were 100, 90.1, and 91.1% in children <5 years old, children aged 5–18 years old, and adults ≥ 18 years old, respectively. Combination with allergic asthma and mono- or multi-sensitization to other aeroallergens did not affect the dropout rates. The most common self-reported reasons for dropouts were refusal of continuation, dissatisfaction with the efficacy, transition to SCIT, and adverse effects. Refusal of continuation increased with age, whereas transition to SCIT decreased with age. Ninety-seven cases transitioned from SLIT to SCIT, and the transition rates increased with time. Comorbid allergic asthma did not affect the transition rates. However, multi-sensitization was associated with a slightly higher rate of transition to SCIT. The most common reason for the transition was dissatisfaction with the efficacy (54.6%), which was only reported by patients older than 5 years. For children who began SLIT at younger than 5 years old, the most common reason (81.2%) for transition was age reaching 5 years.Conclusions: HDM-SLIT has a very high dropout rate, which is mainly due to refusal of continuation and dissatisfaction with the efficacy. Transitioning from SLIT to SCIT may help keep these patients on AIT and thus increase adherence and long-term efficacy.
“…Data on the SS were available in all 20 studies including a total of 858 patients. 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 Data on MS were available in 6 NRS (252 patients) and 7 RCT (160 patients) ( Fig 1 ). Fig 1 Study selection.…”
Section: Resultsmentioning
confidence: 99%
“…All the NRS were prospective except 3, which were retrospective. 29 , 31 , 36 There were 3 multicenter studies. 28 , 32 , 41…”
Section: Resultsmentioning
confidence: 99%
“…The mean of the mean age of patients from the individual studies was 21 ± 13.9 years and was greater in RCT (mean age 27.3 ± 18.7 years) than NRS (16.5 ± 7.1 years). Nine studies included patients sensitized only to HDM (monosensitized), 26 , 27 , 30 , 35 , 36 , 40 , 41 , 43 , 44 4 studies included both HDM-monosensitized patients and patients sensitized to allergens other than HDM (polysensitized), 28 , 39 , 42 , 45 and 7 studies did not report whether the patients were mono- or polysensitized. 29 , 31 , 32 , 33 , 34 , 37 , 38 All the studies included patients with ARC (in the Tosca et al 31 study, the proportion of patients with ARC was 84.6%).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
